Immunosuppressive exosomes: A new approach for treating arthritis

80Citations
Citations of this article
119Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease and one of the leading causes of disability in the USA. Although certain biological therapies, including protein and antibodies targeting inflammatory factors such as the tumor necrosis factor, are effective in reducing symptoms of RA, these treatments do not reverse disease. Also, although novel gene therapy approaches have shown promise in preclinical and clinical studies to treat RA, it is still unclear whether gene therapy can be readily and safely applied to treat the large number of RA patients. Recently, nanosized, endocytic-derived membrane vesicles exosomes were demonstrated to function in cell-to-cell communication and to possess potent immunoregulatory properties. In particular, immunosuppressive DC-derived exosomes and blood plasma- or serum-derived exosomes have shown potent therapeutic effects in animal models of inflammatory and autoimmune disease including RA. This paper discusses the current knowledge on the production, efficacy, mechanism of action, and potential therapeutic use of immunosuppressive exosomes for arthritis therapy. © Copyright 2012 Chenjie Yang and Paul D. Robbins.

Cite

CITATION STYLE

APA

Yang, C., & Robbins, P. D. (2012). Immunosuppressive exosomes: A new approach for treating arthritis. International Journal of Rheumatology. https://doi.org/10.1155/2012/573528

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free